Allergan PLC (AGN)

190.48
0.79 0.42
NYSE : Health Care
Prev Close 189.69
Open 190.17
Day Low/High 190.00 / 192.07
52 Wk Low/High 184.50 / 317.48
Volume 1.36M
Avg Volume 4.74M
Exchange NYSE
Shares Outstanding 374.95M
Market Cap 71.38B
EPS 10.00
P/E Ratio 13.94
Div & Yield 2.80 (1.50%)

Latest News

Weekly Roundup

OPEC deal is among the highlights as markets finish off an explosive November. In the portfolio, we adjust the size of some of our positions.

Stocks Fluctuate in Choppy Trade as Bank Shares Pull Back

Stocks Fluctuate in Choppy Trade as Bank Shares Pull Back

Stocks fluctuate on Friday afternoon in choppy trading as banks beat a retreat after days of gains.

Stocks Mixed as November Jobs Solidify Chances of December Rate Hike

Stocks Mixed as November Jobs Solidify Chances of December Rate Hike

Stocks hold mixed on Friday after U.S. jobs gains in November solidify the chances of a December rate hike.

U.S. Stocks Turn Mixed as Economy Adds 178,000 Jobs in November

U.S. Stocks Turn Mixed as Economy Adds 178,000 Jobs in November

U.S. stocks were mixed Friday, despite a better than expected jobs report.

Amgen And Allergan Submit Biosimilar Marketing Authorization Application To European Medicines Agency For ABP 215, A Biosimilar Candidate To Bevacizumab

Amgen And Allergan Submit Biosimilar Marketing Authorization Application To European Medicines Agency For ABP 215, A Biosimilar Candidate To Bevacizumab

Supported by Phase 3 Study in Patients With Non-Squamous Non-Small Cell Lung Cancer

Stock Futures Hold Lower After U.S. Adds 178,000 Jobs

Stock Futures Hold Lower After U.S. Adds 178,000 Jobs

Stock futures hold lower on Friday after U.S. job gains in November come in around forecasts.

The Most Admired Corporate Dealmakers in a Record Year

The Most Admired Corporate Dealmakers in a Record Year

In a record year for acquisitions, 18 companies from across the spectrum were singled out by M&A professionals for doing deals that got results.

Allergan Seeks to Reassure Antsy Investors but Will They Buy It?

Allergan Seeks to Reassure Antsy Investors but Will They Buy It?

Will investors want to wait 12 to 18 months to see Allergan's deals pay dividends?

Cramer: Rally Isn't Because Trump's Coming In but Because Fed's Going Out

Cramer: Rally Isn't Because Trump's Coming In but Because Fed's Going Out

Market should still be able to breathe once central-bank prop is removed.

Some 'January Effect' Stock Picks

Some 'January Effect' Stock Picks

Small-caps could also benefit from abating tax-loss selling.

Aegon To Appoint Matthew Rider As CFO

Aegon To Appoint Matthew Rider As CFO

Home Depot, Lowe's, Best Buy: Doug Kass' Views

Home Depot, Lowe's, Best Buy: Doug Kass' Views

Doug Kass shares his thoughts on the Trump world and how large-cap biotechs are doing.

Starbucks, Facebook, Apple: Doug Kass' Views

Starbucks, Facebook, Apple: Doug Kass' Views

Doug Kass shares his thoughts on how faster growth won't be easy and how the debt and deficits are out of control.

Weekly Roundup

The markets reach record highs in a short week as oil and a potential rate hike get much of the attention.

Allergan Could Pay $1 Billion for Chase Pharma

Allergan Could Pay $1 Billion for Chase Pharma

'Milestone payments' could boost deal's $125 million announced price.

Jim Cramer's Top Takeaways: Home Depot, Corbus Pharmaceuticals

Jim Cramer's Top Takeaways: Home Depot, Corbus Pharmaceuticals

Positive results mean a lot for HD and CRBP, says Jim Cramer.

Jim Cramer's 'Mad Money' Recap: Expect More Earnings Surprises

Jim Cramer's 'Mad Money' Recap: Expect More Earnings Surprises

The number and magnitude of earnings surprises has a big impact on the markets, says Jim Cramer.

Allergan Acquires Chase Pharmaceuticals To Expand CNS R&D Pipeline And Build On Commitment To Alzheimer's Disease

Allergan Acquires Chase Pharmaceuticals To Expand CNS R&D Pipeline And Build On Commitment To Alzheimer's Disease

- Acquisition Adds Development Programs Focused on Enabling Improved Treatment in Alzheimer's disease -

Adding to This Health Care Name

We'll buy more Allergan shares, with the risk-reward skewed heavily to the upside.

CEO Saunders' Stake Fails to Bolster Allergan

CEO Saunders' Stake Fails to Bolster Allergan

Previously this month activist Carl Icahn has unloaded most of the stake he built up earlier in the year.

Allergan Receives FDA Clearance For The XEN® Gel Stent, A New Surgical Treatment For Refractory Glaucoma

Allergan Receives FDA Clearance For The XEN® Gel Stent, A New Surgical Treatment For Refractory Glaucoma

-- An Ab Interno Approach to Reduce Intraocular Pressure in Patients with Refractory Glaucoma -

Allergan, Apple and Cisco: Doug Kass' Views

Allergan, Apple and Cisco: Doug Kass' Views

Doug Kass shares his thoughts on considering the contrary and shorting the Cisco Kid.

Facebook, Home Depot, Disney: Doug Kass' Views

Facebook, Home Depot, Disney: Doug Kass' Views

Doug Kass shares his thoughts on contrariness and his takeaways and observations on the market.

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Allergan Plc To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Allergan Plc To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...

No to Closed-End Muni Bond Funds; Cara on a Run: Best of Kass

No to Closed-End Muni Bond Funds; Cara on a Run: Best of Kass

In highlights from this week's trading diary and posts, Kass tells us about how to say no to closed-end muni bond funds and why Cara Therapeutics is on a run.